+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Type (Type 1, Type 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 100 Pages
  • June 2024
  • Region: Global
  • Grand View Research
  • ID: 5983030
Description Jump to:
The global antidiabetics market size is expected to reach USD 184.47 billion by 2030, expanding at a CAGR of 12.23% from 2023 to 2030. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights

  • The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
  • North America was the most mature antidiabetics market in 2023 accounting for over 41.51% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
  • Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
  • Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
  • The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Drug Class Segment
1.1.1.2. Diabetes Type Segment
1.1.1.3. Distribution Channel Segment
1.1.1.4. Route of Administration Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Rising Diabetes Prevalence
3.4.2. Advancements in Research and Technology
3.4.3. Increasing Awareness and Early Intervention
3.5. Market Restraint Analysis
3.5.1. High Development Costs
3.5.2. Side Effects and Safety Concerns
3.6. Industry Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Drug Class Business Analysis
4.1. Antidiabetics Market: Drug Class Movement Analysis
4.2. Insulin
4.2.1. Insulin Market, 2018-2030 (USD Million)
4.2.1.1. Insulin Market, By Type
4.2.1.1.1. Long-acting insulin
4.2.1.1.1.1. Long-acting insulin market, 2018-2030 (USD Million)
4.2.1.1.2. Premix insulin
4.2.1.1.2.1. Premix insulin market, 2018-2030 (USD Million)
4.2.1.1.3. Fast-acting insulin
4.2.1.1.3.1. Fast-acting insulin market, 2018-2030 (USD Million)
4.2.1.1.4. Human insulin
4.2.1.1.4.1. Human insulin market, 2018-2030 (USD Million)
4.3. GLP-1 Receptor Agonists
4.3.1. GLP-1 Receptor Agonists Market, 2018-2030 (USD Million)
4.4. DPP- 4 Inhibitors
4.4.1. DPP- 4 Inhibitors Market, 2018-2030 (USD Million)
4.5. SGLT2 Inhibitors
4.5.1. SGLT2 Inhibitors Market, 2018-2030 (USD Million)
4.6. DPP-4 Inhibitors
4.6.1. DPP- 4 Inhibitors Market, 2018-2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Diabetes Type Business Analysis
5.1. Antidiabetics Market: Diabetes Type Class Movement Analysis
5.2. Type 1
5.2.1. Type 1 Market, 2018-2030 (USD Million)
5.3. Type 2
5.3.1. Type 2 Market, 2018-2030 (USD Million)
Chapter 6. Route of Administration Business Analysis
6.1. Antidiabetics Market: Route of Administration Movement Analysis
6.2. Oral
6.2.1. Oral Market, 2018-2030 (USD Million)
6.3. Subcutaneous
6.3.1. Subcutaneous Market, 2018-2030 (USD Million)
6.4. Intravenous
6.4.1. Intravenous Market, 2018-2030 (USD Million)
Chapter 7. Distribution Channel Business Analysis
7.1. Antidiabetics Market: Distribution Channel Movement Analysis
7.2. Online Pharmacies
7.2.1. Online Pharmacies Market, 2018-2030 (USD Million)
7.3. Hospital Pharmacies
7.3.1. Hospital Pharmacies, Market, 2018-2030 (USD Million)
7.4. Retail Pharmacies
7.4.1. Retail Pharmacies Market, 2018-2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Antidiabetics Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America Antidiabetics Market, 2018-2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. U.S. Antidiabetics Market, 2018-2030 (USD Million)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Canada Antidiabetics Market, 2018-2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe Antidiabetics Market, 2018-2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. UK Antidiabetics Market, 2018-2030 (USD Million)
8.3.4. Germany
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Germany Antidiabetics Market, 2018-2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. France Antidiabetics Market, 2018-2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Italy Antidiabetics Market, 2018-2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Spain Antidiabetics Market, 2018-2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Denmark Antidiabetics Market, 2018-2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Sweden Antidiabetics Market, 2018-2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Norway Antidiabetics Market, 2018-2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific Antidiabetics Market, 2018-2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Japan Antidiabetics Market, 2018-2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. China Antidiabetics Market, 2018-2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. India Antidiabetics Market, 2018-2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Australia Antidiabetics Market, 2018-2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Thailand Antidiabetics Market, 2018-2030 (USD Million)
8.4.8. South Korea
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. South Korea Antidiabetics Market, 2018-2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America Antidiabetics Market, 2018-2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Brazil Antidiabetics Market, 2018-2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Mexico Antidiabetics Market, 2018-2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Argentina Antidiabetics Market, 2018-2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Antidiabetics Market, 2018-2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. South Africa Antidiabetics Market, 2018-2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Saudi Arabia Antidiabetics Market, 2018-2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. UAE Antidiabetics Market, 2018-2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Kuwait Antidiabetics Market, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Share Analysis, 2022
9.4. Company Profiles/Listing
9.4.1. AstraZeneca plc
9.4.1.1. Overview
9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Bayer AG
9.4.2.1. Overview
9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Takeda Pharmaceutical Company Limited
9.4.3.1. Overview
9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Eli Lilly and Company
9.4.4.1. Overview
9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Boehringer Ingelheim
9.4.5.1. Overview
9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Bristol-Myers Squibb Company
9.4.6.1. Overview
9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Pfizer, Inc.
9.4.7.1. Overview
9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Johnson & Johnson Services Inc.
9.4.8.1. Overview
9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Merck & Co. Inc
9.4.9.1. Overview
9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Novartis AG
9.4.10.1. Overview
9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global antidiabetics market, by drug class, 2018-2030 (USD Million)
Table 3 Global antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 4 Global antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 5 Global antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 6 Global antidiabetics market, by region, 2018-2030 (USD Million)
Table 7 North America antidiabetics market, by country, 2018-2030 (USD Million)
Table 8 North America antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 9 North America antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 10 North America antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 11 North America antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 12 U.S. antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 13 U.S. antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 14 U.S. antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 15 U.S. antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 16 Canada antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 17 Canda antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 18 Canada antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 19 Canada antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 20 Europe antidiabetics market, by country, 2018-2030 (USD Million)
Table 21 Europe antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 22 Europe antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 23 Europe antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 24 Europe antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 25 UK antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 26 UK antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 27 UK antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 28 UK antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 29 Germany antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 30 Germany antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 31 Germany antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 32 Germany antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 33 France antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 34 France antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 35 France antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 36 France antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 37 Italy antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 38 Italy antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 39 Italy antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 40 Italy antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 41 Spain antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 42 Spain antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 43 Spain antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 44 Spain antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 45 Denmark antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 46 Denmark antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 47 Denmark antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 48 Denmark antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 49 Sweden antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 50 Sweden antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 51 Sweden antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 52 Sweden antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 53 Norway antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 54 Norway antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 55 Norway antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 56 Norway antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 57 Asia Pacific antidiabetics market, by country, 2018-2030 (USD Million)
Table 58 Asia Pacific antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 59 Asia Pacific antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 60 Asia Pacific antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 61 Asia Pacific antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 62 Japan antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 63 Japan antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 64 Japan antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 65 Japan antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 66 China antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 67 China antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 68 China antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 69 China antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 70 India antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 71 India antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 72 India antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 73 India antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 74 Australia antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 75 Australia antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 76 Australia antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 77 Australia antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 78 Thailand antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 79 Thailand antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 80 Thailand antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 81 Thailand antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 82 South Korea antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 83 South Korea antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 84 South Korea antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 85 South Korea antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 86 Latin America antidiabetics market, by country, 2018-2030 (USD Million)
Table 87 Latin America antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 88 Latin America antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 89 Latin America antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 90 Latin America antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 91 Brazil antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 92 Brazil antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 93 Brazil antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 94 Brazil antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 95 Mexico antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 96 Mexico antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 97 Mexico antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 98 Mexico antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 99 Argentina antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 100 Argentina antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 101 Argentina antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 102 Argentina antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 103 Middle East & Africa antidiabetics market, by country, 2018-2030 (USD Million)
Table 104 Middle East & Africa antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 105 Middle East & Africa antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 106 Middle East & Africa antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 107 Middle East & Africa antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 108 South Africa antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 109 South Africa antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 110 South Africa antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 111 South Africa antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 112 Saudi Arabia antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 113 Saudi Arabia antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 114 Saudi Arabia antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 115 Saudi Arabia antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 116 UAE antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 117 UAE antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 118 UAE antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 119 UAE antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 120 Kuwait antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 121 Kuwait antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 122 Kuwait antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 123 Kuwait antidiabetics market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 Antidiabetics market segmentation
Figure 8 Market snapshot, 2022
Figure 9 Market trends & outlook
Figure 10 Market driver relevance analysis (current & future impact)
Figure 11 Market restraint relevance analysis (current & future impact)
Figure 12 SWOT analysis, by factor (political & legal, economic, and technological)
Figure 13 Porter’s Five forces analysis
Figure 14 Market penetration & growth prospect mapping, 2022
Figure 15 Global antidiabetics market: drug class movement analysis
Figure 16 Global antidiabetics market, for Insulin, 2018-2030 (USD Million)
Figure 17 Global antidiabetics market, for GLP-1 receptor agonists, 2018-2030 (USD Million)
Figure 18 Global antidiabetics market, for DPP- 4 inhibitors, 2018-2030 (USD Million)
Figure 19 Global antidiabetics market, for SGLT2 inhibitors, 2018-2030 (USD Million)
Figure 20 Global antidiabetics market, for others, 2018-2030 (USD Million)
Figure 21 Global antidiabetics market: diabetes type movement analysis
Figure 22 Global antidiabetics market, for type 1, 2018-2030 (USD Million)
Figure 23 Global antidiabetics market, for type 2, 2018-2030 (USD Million)
Figure 24 Global antidiabetics market: route of administration movement analysis
Figure 25 Global antidiabetics market, for oral, 2018-2030 (USD Million)
Figure 26 Global antidiabetics market, for subcutaneous, 2018-2030 (USD Million)
Figure 27 Global antidiabetics market, for intravenous, 2018-2030 (USD Million)
Figure 28 Global antidiabetics market: distribution channel movement analysis
Figure 29 Global antidiabetics market, for online pharmacies, 2018-2030 (USD Million)
Figure 30 Global antidiabetics market, for hospital pharmacies, 2018-2030 (USD Million)
Figure 31 Global antidiabetics market, retail pharmacies, 2018-2030 (USD Million)
Figure 32 Regional marketplace: Key takeaways
Figure 33 Regional outlook, 2022 & 2030
Figure 34 Global antidiabetics market: region movement analysis
Figure 35 North America antidiabetics market, 2018-2030 (USD Million)
Figure 36 U.S. antidiabetics market, 2018-2030 (USD Million)
Figure 37 Canada antidiabetics market, 2018-2030 (USD Million)
Figure 38 Europe antidiabetics market, 2018-2030 (USD Million)
Figure 39 Germany antidiabetics market, 2018-2030 (USD Million)
Figure 40 UK antidiabetics market, 2018-2030 (USD Million)
Figure 41 France antidiabetics market, 2018-2030 (USD Million)
Figure 42 Italy antidiabetics market, 2018-2030 (USD Million)
Figure 43 Spain antidiabetics market, 2018-2030 (USD Million)
Figure 44 Denmark antidiabetics market, 2018-2030 (USD Million)
Figure 45 Sweden antidiabetics market, 2018-2030 (USD Million)
Figure 46 Norway antidiabetics market, 2018-2030 (USD Million)
Figure 47 Asia Pacific antidiabetics market, 2018-2030 (USD Million)
Figure 48 Japan antidiabetics market, 2018-2030 (USD Million)
Figure 49 China antidiabetics market, 2018-2030 (USD Million)
Figure 50 India antidiabetics market, 2018-2030 (USD Million)
Figure 51 Australia antidiabetics market, 2018-2030 (USD Million)
Figure 52 South Korea antidiabetics market, 2018-2030 (USD Million)
Figure 53 Thailand antidiabetics market, 2018-2030 (USD Million)
Figure 54 Latin America antidiabetics market, 2018-2030 (USD Million)
Figure 55 Brazil antidiabetics market, 2018-2030 (USD Million)
Figure 56 Mexico antidiabetics market, 2018-2030 (USD Million)
Figure 57 Argentina antidiabetics market, 2018-2030 (USD Million)
Figure 58 Middle East and Africa antidiabetics market, 2018-2030 (USD Million)
Figure 59 South Africa antidiabetics market, 2018-2030 (USD Million)
Figure 60 Saudi Arabia antidiabetics market, 2018-2030 (USD Million)
Figure 61 UAE antidiabetics market, 2018-2030 (USD Million)
Figure 62 Kuwait antidiabetics market, 2018-2030 (USD Million)

Companies Mentioned

  • AstraZeneca plc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Pfizer, Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc
  • Novartis AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedJune 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 82.37 Billion
Forecasted Market Value ( USD ) by 2030 $ 184.47 Billion
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Antidiabetic Drugs Market by Type, Disease, Patient - Global Forecast 2025-2030 - Product Image

Antidiabetic Drugs Market by Type, Disease, Patient - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Antidiabetics Market Report 2024 - Product Image

Antidiabetics Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Antidiabetics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Antidiabetics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Global Antidiabetics Market by Product Type, by Application, by Distribution channel, and By Region - Product Image

Global Antidiabetics Market by Product Type, by Application, by Distribution channel, and By Region

  • Report
  • 200 Pages
  • Global
From
Antidiabetics Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Antidiabetics Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.